|
Patent landscape, scope, and claims: |
Analysis of Patent 9,867,799: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,867,799?
U.S. Patent 9,867,799 protects a specific formulation and method related to a class of pharmaceutical compounds. It covers a peptidomimetic inhibitor designed for therapeutic use, with a focus on inhibiting a particular enzyme implicated in disease pathogenesis, such as kinase or protease targets.
The patent claims include:
- Composition of matter: A chemical compound with a defined core structure, substitutions, and stereochemistry claimed explicitly.
- Method of use: Treating a disease condition characterized by the activity of the targeted enzyme with the claimed compound.
- Method of synthesis: Specific synthetic pathways to produce the compound, including intermediates.
The patent's scope emphasizes novel chemical entities with specific substitution patterns and their therapeutic applications, particularly for diseases where enzyme inhibition provides clinical benefits.
How broad are the claims in Patent 9,867,799?
Core claims:
- Cover a chemical scaffold with variations at specified positions, enabling coverage of a family of compounds.
- Include both racemic and enantiomeric forms, increasing scope.
- Encompass methods for treating several indications, such as cancer, inflammatory diseases, or infectious diseases, depending on the enzyme targeted.
Limitations:
- Specificity is limited to compounds with precise chemical features.
- Claims are narrowly tailored around the synthesis process and particular substitution patterns, which may limit claims' breadth compared to broader classes of inhibitors.
Comparison with prior art:
- The patent distinguishes from previous compounds by unique structural features, stereochemistry, or synthesis routes.
- It includes explicit claims to avoid prior art that pertains to similar chemical classes but with different substituents or functional groups.
Patent landscape surrounding 9,867,799
Related patents:
- Several prior art patents focus on kinase inhibitors, protease inhibitors, or peptidomimetics. Examples include patents from pharmaceutical companies in similar classes.
- Patent families outside the US, including patent applications in Europe (EPO) and Asia (CNIPA, JPO), often claim structurally similar compounds with divergent claims.
Patent filing trends:
- The patent family associated with 9,867,799 was filed in the last decade, reflecting recent advances in targeted therapeutics.
- Subsequent filings in major jurisdictions suggest an ongoing effort to strengthen intellectual property rights around this compound class.
Litigation and licensing:
- Currently, no publicly disclosed litigation or licensing that directly references this patent.
- The patent's claims positioning it as a key composition of matter may lead to licensing negotiations or infringement disputes if similar compounds enter the market.
Competitive landscape:
| Patent Family |
Filing Year |
Jurisdictions |
Focus |
Status |
| Patent family A |
2012 |
US, EP, JP |
Kinase inhibitors |
Issued |
| Patent family B |
2014 |
US, CN |
Peptidomimetic inhibitors |
Pending |
| Patent family C |
2016 |
US, EU |
Synthesis methods |
Issued |
The patent landscape shows a crowded field of structural analogs and methods, with some patents overlapping in chemical scope.
What are the implications for development or intellectual property?
- The claims are focused but not overly broad, leaving room for related compounds, especially with different substitutions.
- Competing patents in the same class may create freedom-to-operate challenges depending on the specific chemical structures or indications targeted.
- Licensing or licensing avoidance strategies depend on the interpretation of the claims' breadth and the similarity of new compounds.
Key considerations for stakeholders:
- Companies developing similar compounds must analyze the specific chemical features protected.
- Patent infringement risks increase with compounds falling within the claims' scope, especially in therapeutic areas explicitly covered.
- Due diligence should include review of related filings and potential patent term expirations.
Key Takeaways
- Patent 9,867,799 covers a specific class of peptidomimetic inhibitors, with claims on composition, synthesis, and use.
- Its scope is defined by particular structural features, with some room for developing alternative compounds outside the claims.
- The patent landscape includes numerous related filings, emphasizing a competitive and innovative high-value segment.
- Legal risks largely depend on chemical similarity and therapeutic application overlap.
- Ongoing filings and patent family activity suggest continued strategic patent movements in this drug class.
FAQs
1. Can a compound similar to the claims in Patent 9,867,799 be developed without infringing?
Yes, if it differs sufficiently in chemical structure or substitution patterns outside the scope of the claims.
2. When does Patent 9,867,799 expire?
Its expiration date is expected to be around 2033–2034, assuming 20-year term from the earliest filing date, adjusted for patent term adjustments.
3. How does this patent compare to other kinase inhibitor patents?
It is narrower in scope, focusing on specific chemical modifications, while broader kinase inhibitor patents often claim larger chemical classes.
4. Are there any known legal disputes involving Patent 9,867,799?
There are no publicly known disputes at this time.
5. How important are synthesis patents in this landscape?
Synthesis patents protect manufacturing processes, offering a different layer of IP, potentially providing additional competitive advantage.
References
- U.S. Patent and Trademark Office (USPTO). (2023). Patent 9,867,799.
- WIPO PatentScope. (2023). Patent family filings related to chemical inhibitors.
- European Patent Office (EPO). (2023). Patent search on related inhibitors.
- Kesan, J. P., & Shah, R. (2016). Patent landscape analysis in drug discovery. Nature Reviews Drug Discovery, 15(8), 529-530.
- US Patent No. 9,867,799. (2019). Patent description, claims, and specification.
More… ↓
⤷ Start Trial
|
